Phaseline

Targets › CD3G

CD3G (T-cell surface glycoprotein CD3 gamma chain): drug programs, companies and trials

11 programs from 8 companies in 358 trials: 209 Phase 2, 93 Phase 1, 53 Phase 3, 3 Phase 4; Oncology, Immunology, Metabolic and endocrine; next expected readout Jan 2027.

Part of the TCR-CD3 complex present on T-lymphocyte cell surface that plays an essential role in adaptive immune response. When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD247/CD3Z. All CD3 chains contain immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic domain. (UniProt, P09693)

Open in Phaseline: the race on CD3G, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
PfizerElranatamab
T cell surface glycoprotein CD3 binding agent; Tumor necrosis factor receptor superfamily member 17 binding agent
CD3E, CD3G, CD3D, TNFRSF17Phase 4Multiple Myeloma; Multiple Myeloma, Newly Diagnosed; Relapsed Refractory Multiple Myeloma (RRMM); Refractory Multiple Myeloma …May 2027
RocheGlofitamab
B-lymphocyte antigen CD20 binding agent; T cell surface glycoprotein CD3 binding agent
MS4A1, CD3E, CD3G, CD3DPhase 3Lymphoma; Large B-Cell Lymphoma; Diffuse Large B-cell Lymphoma; Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma …Jan 2027
RocheMosunetuzumab
T cell surface glycoprotein CD3 binding agent; B-lymphocyte antigen CD20 binding agent
CD3E, CD3G, CD3D, MS4A1Phase 3Non-Hodgkin Lymphoma; Relapsed or Refractory Follicular Lymphoma; Lupus; B-cell Non-Hodgkin Lymphoma …Feb 2027
GenmabEpcoritamab
B-lymphocyte antigen CD20 binding agent; T cell surface glycoprotein CD3 binding agent
MS4A1, CD3E, CD3G, CD3DPhase 3Diffuse Large B-Cell Lymphoma; Diffuse Large B-cell Lymphoma; Follicular Lymphoma (FL); Non-Hodgkin Lymphoma …Mar 2027
Johnson & Johnson (Janssen)Talquetamab
T cell surface glycoprotein CD3 binding agent; G-protein coupled receptor family C group 5 member D binding agent
CD3E, CD3G, CD3D, GPRC5DPhase 3Multiple Myeloma; Hematological Malignancies; Relapsed/ Refractory Multiple Myeloma; Multiple Myeloma (MM) …Apr 2027
Johnson & Johnson (Janssen)Teclistamab
T cell surface glycoprotein CD3 binding agent; Tumor necrosis factor receptor superfamily member 17 binding agent
CD3E, CD3G, CD3D, TNFRSF17Phase 3Multiple Myeloma; Hematological Malignancies; Relapsed/ Refractory Multiple Myeloma; Multiple Myeloma (MM) …Apr 2027
AmgenTarlatamab
T cell surface glycoprotein CD3 binding agent; Delta-like protein 3 binding agent
CD3E, CD3G, CD3D, DLL3Phase 3Small Cell Lung Cancer; Small Cell Lung Cancer (SCLC); Small-cell Lung Cancer; Extensive-Stage Small-Cell Lung Cancer …Apr 2027
AmgenBlinatumomab
T cell surface glycoprotein CD3 cross-linking agent; B-lymphocyte antigen CD19 cross-linking agent
CD3E, CD3G, CD3D, CD19Phase 3Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL); B Precursor Acute Lymphoblastic Leukemia; Systemic Lupus Erythematosus; B Cell Precursor Acute Lymphoblastic Leukemia …Oct 2027
Regeneron PharmaceuticalsOdronextamab
B-lymphocyte antigen CD20 binding agent; T cell surface glycoprotein CD3 binding agent
MS4A1, CD3E, CD3G, CD3DPhase 3Follicular Lymphoma (FL); Diffuse Large B-cell Lymphoma (DLBCL); B-Cell Non-Hodgkin Lymphoma (B-NHL); Relapsed/Refractory Follicular Lymphoma …Feb 2028
Tiziana Life SciencesForalumab (TZLS-401)
T cell surface glycoprotein CD3 inhibitor
CD3E, CD3G, CD3DPhase 2Non-Active Secondary Progressive Multiple Sclerosis; Secondary Progressive Multiple Sclerosis; Multiple System Atrophy; DementiaApr 2027
Children's Oncology GroupFlotetuzumab
Interleukin-3 receptor subunit alpha binding agent; T cell surface glycoprotein CD3 binding agent
IL3RA, CD3E, CD3G, CD3DPhase 1Recurrent Acute Myeloid LeukemiaMar 2027

Conditions

Multiple Myeloma (56) Follicular Lymphoma (13) Acute Lymphoblastic Leukemia (13) Diffuse Large B-Cell Lymphoma (8) Lymphoma (7) Large B-cell Lymphoma (7) B Acute Lymphoblastic Leukemia (6) Recurrent Diffuse Large B-Cell Lymphoma (5) Multiple Myeloma (MM) (5) Non-Hodgkin Lymphoma (5) Mantle Cell Lymphoma (5) B-cell Acute Lymphoblastic Leukemia (5)

Modalities

mixed (9), antibody (2)

Companies

Amgen (2) Roche (2) Johnson & Johnson (Janssen) (2) Regeneron Pharmaceuticals (1) Tiziana Life Sciences (1) Pfizer (1) Genmab (1) Children's Oncology Group (1)

Related targets

CD3E (11) CD3D (11) MS4A1 (4) TNFRSF17 (2) DLL3 (1) GPRC5D (1) CD19 (1) IL3RA (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.